Sivik Global Healthcare LLC Has $5.74 Million Holdings in Danaher Co. (NYSE:DHR)

Sivik Global Healthcare LLC trimmed its holdings in shares of Danaher Co. (NYSE:DHR - Free Report) by 16.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,000 shares of the conglomerate's stock after selling 5,000 shares during the period. Danaher comprises 3.0% of Sivik Global Healthcare LLC's holdings, making the stock its 12th largest position. Sivik Global Healthcare LLC's holdings in Danaher were worth $5,739,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the stock. Decker Retirement Planning Inc. acquired a new stake in Danaher in the 4th quarter valued at about $31,000. Teachers Insurance & Annuity Association of America bought a new stake in Danaher in the third quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher in the third quarter valued at approximately $40,000. FSA Wealth Management LLC bought a new position in shares of Danaher during the 3rd quarter worth approximately $50,000. Finally, Darwin Wealth Management LLC acquired a new position in shares of Danaher during the 3rd quarter worth approximately $55,000. Institutional investors own 79.05% of the company's stock.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the business's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 10.90% of the company's stock.

Danaher Price Performance

NYSE DHR traded down $8.27 on Monday, hitting $214.47. 4,124,349 shares of the company's stock were exchanged, compared to its average volume of 3,684,531. Danaher Co. has a 52 week low of $214.42 and a 52 week high of $281.70. The stock has a 50-day moving average of $235.40 and a 200-day moving average of $253.09. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock has a market cap of $154.91 billion, a price-to-earnings ratio of 40.62, a P/E/G ratio of 2.80 and a beta of 0.83.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the firm earned $2.09 EPS. Analysts expect that Danaher Co. will post 7.77 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date was Friday, December 27th. Danaher's dividend payout ratio is 20.45%.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research analyst reports. Wolfe Research raised shares of Danaher from a "peer perform" rating to an "outperform" rating and set a $285.00 price objective for the company in a research report on Thursday, October 31st. TD Cowen upped their price target on shares of Danaher from $310.00 to $315.00 and gave the company a "buy" rating in a research note on Wednesday, October 23rd. Wells Fargo & Company cut their price objective on shares of Danaher from $280.00 to $240.00 and set an "equal weight" rating for the company in a research report on Thursday. Bank of America raised Danaher from a "neutral" rating to a "buy" rating and set a $290.00 target price on the stock in a research report on Friday, December 13th. Finally, Raymond James reissued a "market perform" rating on shares of Danaher in a report on Monday. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Danaher currently has a consensus rating of "Moderate Buy" and an average target price of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.